Podcasts about biotech

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode, Lyle Small, Founder and CEO at Lahjavida, a dye drug conjugate start-up, talks about creating the famous color-changing technology that turned the mountains blue on cold Coors Light beer cans, to launching a dye-drug conjugate startup developing targeted cancer therapies. Small talks through Lahjavida's early preclinical work and the ongoing animal studies he hopes will secure an IND filing by 2027, his experience with scaling up manufacturing of new technologies, and his approach to leadership and company culture.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

How far would you go to reshape medicine?Dr. Janakan Krishnarajah has led over 100 clinical trials, transitioning from bedside physician to a biotech disruptor. On this episode, he reveals that turning point—and the early challenge that redefined his path.Next: he developed Wafermine, the world's first sublingual ketamine wafer for acute pain—a bold alternative in the opioid era. How did he convince skeptics this wasn't anesthesia or recreational use, but revolutionary pain management? We dig into the story behind the innovation and the FDA and EMA approvals that made Phase 3 trials possibleAnd then came Xativa, a freeze-dried medicinal cannabis wafer. We explore how iX Biopharma pushed this disruptive therapy into mainstream medicine—despite regulatory headwinds and stigma.This isn't all success: Dr. Krishnarajah opens up about a major setback when dreaming big went wrong—and the lessons that changed his leadership style. You'll hear why he lives by “pursue life with your whole heart, without regrets,” and how that mantra shapes innovation and company culture at iX Biopharma.From the explosive growth of the global medicinal cannabis market to the rise of longevity medicine, this conversation spans the past, present, and future of healthcare. What does sublingual NAD for longevity really hold? Is it breakthrough or overhyped? Only one way to find out.Want the full story behind modern medicine's boldest bets? Tune in now.Learn more about Dr. Janakan Krishnarajah and iX Biopharma:Official site: ixbiopharma.comProduct pipeline & platform WaferiX: HEREWe are two sports chiropractors, seeking knowledge from some of the best resources in the world of health. From our perspective, health is more than just “Crackin Backs” but a deep dive into physical, mental, and nutritional well-being philosophies. Join us as we talk to some of the greatest minds and discover some of the most incredible gems you can use to maintain a higher level of health. Crackin Backs Podcast

What makes a biotech-CRO partnership truly work? Claire Riches, VP, Clinical Solutions, Citeline, and Matt Simmons, Senior Director, Oncology Strategy, IQVIA Biotech, share the secrets behind winning biotech-CRO partnerships, covering collaboration, transparent budgeting, regulatory navigation, and recruitment strategies, with essential insights to help biotechs succeed from their first RFP to global trials. View the video series and find out more information here: https://www.citeline.com/biotech

What if a drug could help chemotherapy patients continue treatment without painful side effects? Hoth Therapeutics (NASDAQ: HOTH) is making that possible by developing innovative treatments that address unmet medical needs and help patients maintain their therapy safely.In this interview, CEO Robb Knie discusses HT001, the company's lead drug currently in Phase 2 trials for chemotherapy-induced rash, and HTKIT, which shows promise in cancer treatment. He also shares how the company is advancing programs for Alzheimer's and obesity, including an obesity drug licensed from the U.S. Department of Veterans Affairs.With a diversified pipeline, a patient-focused approach, and strategic use of AI to de-risk and accelerate development, Hoth Therapeutics is positioning itself as a biotech company to watch.Learn more about Hoth Therapeutics: https://hoththerapeutics.comWatch the full YouTube interview here: https://youtu.be/AYQa3g6dVLA?si=w_zDH0TaSxP3m6JiAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

In this episode of The Tech Leader's Playbook, Avetis Antaplyan sits down with Susan Ruediger, Founder and Chief Mission Officer of the CMT Research Foundation (CMTRF), and Laura MacNeill, the organization's CEO. Together, they explore how patient-led research is revolutionizing drug development and catalyzing billion-dollar outcomes. Susan shares the remarkable story of CMTRF's $128,000 seed investment in DTX Pharma that led to a $1 billion Novartis acquisition — a masterclass in strategic risk-taking and venture philanthropy. Laura explains how CMTRF's unique “go-out-of-business” mission drives urgency, focus, and impact, while also inspiring other nonprofits to adopt similar models. The conversation dives deep into storytelling's role in galvanizing donors, the importance of milestones and reinvestment, and how rare disease foundations can unlock breakthroughs for broader neurodegenerative diseases like ALS, Parkinson's, and Alzheimer's. Whether you're a biotech leader, investor, or nonprofit executive, this episode offers actionable lessons on focus, partnerships, and creating outsized impact with limited resources.TakeawaysPatient-led research can de-risk and accelerate drug development.$128K seed funding led to a $1B Novartis acquisition.CMTRF uses a venture-philanthropy model with milestone-based funding.Mission: fund treatments, find a cure, close the foundation.Storytelling drives awareness, donations, and partnerships.Early investments keep promising science alive.Biotech partnerships share risk and leverage expertise.Novartis validated CMT as a major market opportunity.Rare disease focus offers faster FDA pathways.Staying laser-focused means saying no to distractions.Chapters00:00 Intro & Guest Welcome01:20 From Grassroots Donations to Billion-Dollar Deals02:30 Understanding CMT and Its Impact05:00 Finding the Right Delivery Vehicle for Drugs07:40 The $128K Bet That Changed Everything09:50 Other Success Stories & Market Signaling13:00 The Venture-Philanthropy Model Explained16:30 The Power of Milestones and Flexibility18:45 Reinvestment and Sustainable Funding21:30 Role of Storytelling and Strategy in Movement Building26:10 Velocity Campaign & Raising $20M27:25 Why Biotechs Care About Rare Diseases31:50 CMT as a Gateway Indication for Neurodegenerative Disease33:30 Staying Focused and Saying No38:30 The Drug Development Lifecycle and Staying Mission-Aligned42:10 How to Get Involved and Follow CMTRF's Work45:10 Personal & Business Advice for Leaders48:30 Favorite Books and Final Thoughts52:00 Closing Remarks and Call to ActionSusan Ruediger's Social Media Links:https://www.linkedin.com/in/susan-ruediger/Laura MacNeill's Social Media Links:https://www.linkedin.com/in/laura-macneill-m-b-a-97633732/CMT Research Foundation's Website:https://cmtrf.org/Resources and Links:https://www.hireclout.comhttps://www.podcast.hireclout.comhttps://www.linkedin.com/in/hirefasthireright

A criação de centros de patologia digital para atendimento no Sistema Único de Saúde (SUS) tem como objetivo transformar o acesso ao diagnóstico oncológico no Brasil. Com o uso de inteligência artificial e lâminas digitalizadas, será possível acelerar a emissão de laudos, reduzir gargalos e garantir que pacientes em regiões remotas tenham acesso a especialistas de referência.Neste episódio do podcast Biotech and Health, Laura Murta e Camila Pepe conversam com o médico Vitor Piana, diretor-geral do A.C.Camargo Cancer Center, sobre o projeto do Super Centro para Diagnóstico de Câncer lançado pelo Ministério da Saúde e os impactos da tecnologia na rotina da oncologia brasileira.O convidado explica como funcionará a rede de até oito centros digitais, capazes de processar até mil biópsias por dia, e detalha como a IA pode apoiar patologistas na classificação de tumores, aumentar a eficiência dos laudos e abrir caminho para uma nova era de precisão no diagnóstico.

Join us in this exciting episode of The Edge of Show as we dive deep into the world of Bitcoin DeFi with two industry leaders: MacLane Wilkison, co-founder and CEO of Threshold Labs, and Jameel Khalfan, head of ecosystem development at Sui Foundation.In this episode, we explore:The transformative potential of TBDC (Threshold Bitcoin Decentralized Currency) and how it is powering Bitcoin's breakout moment on the SWE ecosystem.The rapid evolution of Bitcoin DeFi and the seamless bridging and yield strategies that are emerging.Insights into the future of Bitcoin as a dynamic financial asset and its role in the broader DeFi landscape.Discover how the integration of Bitcoin with decentralized finance is reshaping the financial ecosystem, making it more accessible and user-friendly. We also discuss the importance of security, liquidity, and the collaborative efforts between Threshold and SWE to foster innovation and growth in the Bitcoin space.Whether you're a seasoned crypto enthusiast or just starting your journey, this episode is packed with valuable insights and exciting developments in the world of Bitcoin and DeFi.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

Wednesday, September 10, 2025. Week 37. CAMP4 Press Release:  https://www.linkedin.com/posts/caleb-moore-4382704_syngap1-activity-7371545171047628800-zVqR   Let me tell you a story: EW Story, concern over viability of C4. Easy to follow financials, Mrkt Cap and Net assets of ~$40M.  Net income/EBITDA of -$12.6M in Q2.   Running Phase I / II trials and ramping up for Phase III, not cheap.  They need more than they had and capital is hard to get in this market. But here is the good part, the data is solid, the team is strong, and the SYNGAP1 Ecosystem is excited to have a first mover. SRF was thrilled to be invited, not just because we believe in C4, but because we wanted to send a meaningful signal to other investors that we are working closely with C4 and are eager to support their success.  I believe that our investment, while modest, sent that signal and helped this raise become oversubscribed. The board worked hard on this one. Now for hard questions: Are we conflicted? No.  We will transparently share info about all trials for products with good data.  ( See #S10e172 for ASGCT Data https://youtu.be/9xO1TcO1Eus )  Will other companies be upset?  Unlikely.  Stoke and Praxis are the only companies publicly working on SYNGAP1 that are close to this point and they are not worried about financial viability, but if they do want to do a raise for their SYNGAP1 program, they should certainly call us. What will other companies think? Indeed we are de-risking the disease by showing that our kids are modifiable with ASOs which are the majority of the therapies in scope.  This is a huge favor to others looking at this space.   Isn't this taking a risk with our funds?  Depends.  But if it is, it's a risk worth taking.  Remember we are the smallest investor, we only committed up to $1M, so other professional biotech investors put in $99M. What was the process?  C4 came to us, we decided it was worth talking to the board who had multiple discussions but we said yes in less than a week and that was last week. When is the trial? 2H26 Less than a year from now.  With this financing, I am sure of it. As I write this, the $CAMP stock closed up $0.80 or +40%.  Which is solid.  The market is starting to agree with the wise investors and SRF!  Yes we need a cure.  https://www.linkedin.com/posts/curesyngap1_savekramerdavis-activity-7371607032807763968-PVfG   See you Friday: Beacon of Hope September 12, 2025 - Boston, MA cureSYNGAP1.org/Beacon25   SOCIAL MATTERS - 4,311 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,430 YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,286 Twitter https://twitter.com/cureSYNGAP1  - 46k Insta https://www.instagram.com/curesyngap1/    Episode 182 of #Syngap10 #CureSYNGAP1 #Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

Sales legend and trainer Steve Gielda—co-founder of Ignite Selling—joins Samuel to break down what truly drives performance in medical device, pharma, biotech, and diagnostics. Steve traces his path from selling 3M copiers out of a van to leading life-sciences consulting with Neil Rackham (of SPIN Selling) and building Ignite's simulation-based, gamified training that accelerates pipelines and product launches. We get tactical fast: how today's top reps think strategically, map real stakeholders (beyond the “friendly” contacts), and use smarter questions that challenge clinical and business assumptions—not just needs. Steve explains when SPIN still shines, where Challenger-style questions raise the bar, and why role-playing strategy is as critical as role-playing the call. For frontline managers, Steve lays out the playbook: coach early in the pipeline, ask more than you tell, know when to sell vs. when to coach, and—yes—let your reps fail on safe calls so they learn to win without you. We dive into work ethic vs. knowledge, turning average reps into top performers, and the signals that a high producer is (or isn't) ready for leadership. If you want practical frameworks to sharpen your questioning, focus your account strategy, and elevate your team's coaching culture, this episode delivers candid insights you can apply on your very next call. Connect with Steve: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

Enveda Biosciences is using AI to decode nature's vast chemical library and transform it into breakthrough medicines. Founded in 2019 by Viswa Colluru, the company is advancing first-in-class therapies like ENV-294 while cutting the time and cost of drug discovery. Colluru joins Inside the ICE House to share how Enveda is reimagining the playbook for modern medicine and building a healthier future for patients worldwide.

What do biotech boards want to see in a CEO—and what mistakes can quickly derail a company's success? In this episode, host Elaine Hamm, PhD, sits down with Mark Corrigan, MD, one of the most experienced and respected leaders in the biotech industry. From shaping the development of blockbuster drugs to serving as CEO and board member for multiple companies, Mark has a unique perspective on the intersection of science, leadership, and strategy. He shares candid insights on what makes a strong CEO, the role boards should (and shouldn't) play, and how to navigate today's tough financing environment without losing sight of the mission. In this episode, you'll learn: The key qualities that boards value most in biotech CEOs—and the red flags that raise concerns. Why humility, adaptability, and a clear value proposition are essential traits for leadership. How boards and CEOs can partner effectively when money is tight and timelines are long. Tune in to gain board-level insights into biotech leadership and decision-making that can help you shape your own path forward. Links: Connect with Mark Corrigan, MD, and check out Wave Life Sciences, AstronauTx, Silver Creek Pharmaceuticals, Ceretype Neuromedicine, and Cadenza Bio. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Listen to our previous episode on Building Biotech Boards. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novartis recently acquired Tourmaline for $1.4 billion, continuing its investment in cardiovascular treatments. The company has also made other partnerships in the cardiovascular space this year. Biogen is preparing to release new data on its lupus treatments, with analysts praising the company's pipeline. Novartis has been active in mergers and acquisitions, putting over $17 billion into deals this year. The biotech industry is also seeing some activity, with LB filing for a $228 million IPO to support its phase III plans. Overall, companies like Novartis and Biogen are focusing on expanding their portfolios and developing innovative treatments for various diseases.

Michael Sobolik.Gordon Chang. China's Biowarfare Ambitions Threaten US Dominance and Global Health. China's Communist Party develops biowarfare, including ethnic-specific genetic attacks, to achieve strategic dominance over the US. China aims to divert US biotech innovation and control future vaccine distribution, leveraging lessons from COVID-19. US vaccine hesitancy and decreased investment in cutting-edge technology leave it dangerously exposed to future biothreats. 1906 PEKING DRUM TOWER

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.

“Once a scientist, forever a scientist,” says Legend Biotech CEO Ying Huang as he joins Bloomberg Intelligence analyst Sam Fazeli to share his unconventional journey from the lab bench to Wall Street and back to biotech leadership. Dr. Huang explains how a dream led him from equity research to developing one of the most important CAR-T therapies for multiple myeloma. They explore the science behind BCMA targeting, lessons from the pivotal Johnson & Johnson partnership as well as the company’s ambitions in allogeneic and in-vivo therapies.See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A new data release shows that Summit's Keytruda competitor, Ivonescimab, had better overall survival rates in Asian patients compared to those in North America and Europe. Despite this, the drug narrowly missed the statistical significance threshold required by the FDA for approval in Western countries. Meanwhile, Rapport Therapeutics saw a 180% increase in its stock value after positive mid-stage data for its epilepsy pill, and the FDA opted for a consumer "green list" instead of addressing compounded versions of obesity drugs. The FDA's leadership turnover has led to confusion and uncertainty for small and medium biopharma companies. Lilly is seeking individuals who are willing to challenge the status quo in medicine.FDA expert panels are being criticized for lack of balance, with some meetings being one-sided. RFK Jr. faced bipartisan criticism for his anti-vaccine views during a Senate hearing. Meanwhile, Servier committed up to $530 million in an eye cancer deal and Gilead partnered with the US State Department to distribute a drug to low-income countries. The FDA released a new rare disease approval framework and dropped heavily redacted rejection letters. Amidst uncertainty in FDA leadership, small and medium biopharma companies are left without clear guidance for their therapies. Opinion pieces highlight the potential of small molecules in gene therapy for Duchenne muscular dystrophy and criticize the lack of balance in FDA expert panels. The newsletter also includes upcoming events, job listings, and a request for feedback on coverage topics.

Nimbus Therapeutics is transforming drug discovery with computational chemistry and AI to design small molecules that precisely target disease. CEO Abbas Kazimi, who took the helm in March, is driving a “fail fast” approach that balances discipline with innovation. He joins Inside the ICE House to share how Nimbus is scaling its pipeline and shaping the future of precision medicine.

We love to hear from our listeners. Send us a message. On the Business of Biotech this week, Sahir Ali, Ph.D., founder and general partner at Modi Ventures, a family office investing at the intersection of technology and biology, talks about adapting the Markowitz model to improve returns and balance risk, his concept of the "biostack" for making direct investments into life sciences companies, and the revolutionary potential of scientific super intelligence. Ali explains why Houston, Texas is an underrated ecosystem for life sciences, and what AI will mean for medicine and the future of healthcare consumption.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. During a Senate hearing, Robert F. Kennedy Jr. faced criticism for spreading anti-vaccine views and breaking promises regarding vaccines. The FDA released rejection letters for companies like Lykos Therapeutics, Stealth Biotherapeutics, and Regeneron. Ousted CDC director Susan Monarez accused Kennedy of firing her for not supporting Covid-19 recommendations from an advisory panel with "antivaccine rhetoric." Hengrui Pharmaceuticals signed lucrative deals with Merck and GSK, while the FDA promised to release future Complete Response Letters promptly. In other news, Sanofi's anti-OX40 blocker failed in a Phase III study, Gilead partnered with the US State Department for low-income countries, and AC Immune announced workforce cuts. Kennedy was accused of lying during the hearing, and the FDA released a new rare disease approval framework.

The Myths of Biotech Investing Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. Biotech investing differs from tech investing. There's often no revenue traction to assess. The startup must navigate the FDA path while dealing with cutting-edge devices and therapeutics. Here are some myths of biotech investing: Myth 1-Biotech startups are building companies. In many cases, the biotech startup will sell during the clinical trials or at FDA approval. They rarely proceed to launching a business. Myth 2- Biotechs take much longer than tech companies to exit. Most biotech startups exit in the 3 to 5 year range, which is often shorter than tech companies. Myth 3- Regulatory is the key hurdle to overcome. In reality, it's proving the therapeutic works. Most drugs fail in clinical trials and never reach FDA submission. Myth 4-Reimbursement is the key to a successful biotech therapy. In reality, it's showing value to the physician and patient through high efficacy and low toxicity, which is the key to success. Consider these myths in analyzing biotech startups for investment.   Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at:   Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

Eine individualisierte Diagnose ermöglicht Krebspatient:innen eine effektive und schonende Therapie. Doch obwohl die Biotech-Forschung in den letzten Jahren immer wieder große Durchbrüche erzielt hat, kommt davon im Kliniklabor oft nur wenig an - oder viel zu spät. Unsere heutige Gesprächspartnerin, Molekularbiologin und Unternehmerin Dr. Christina Port, hat sich am Anfang ihrer Gründungsreise die Frage gestellt, wie sie diese Lücke zwischen Forschung und klinischer Anwendung schließen kann. Mit ihrem Startup 2NA FISH entwickelte sie eine Plattform, die RNA-Veränderungen im räumlichen Gewebekontext sichtbar macht und so eine differenzierte Diagnose und Behandlung ermöglicht. In der Forschung ist der Ansatz bereits seit Jahren etabliert – doch fehlte es bisher an Verfahren, die ohne teure Spezialgeräte auskommen. Mit KI-unterstützer DNA-Nanotechnologie macht 2NA FISH die Cutting-Edge-Methode jetzt auch für Kliniken erschwinglich. Für diesen Ansatz wurde das Startup bereits mehrfach prämiert, unter anderem mit dem Gründungspreis des Bundeswirtschaftsministeriums. In dieser Podcast-Folge erfahrt ihr, wie aus jahrelanger Laborarbeit ein marktreifes Produkt erwachsen ist und warum die Gründerin auf klare Workflows und frühe Nutzerintegration setzt. Port berichtet von ihrer Entscheidung, auf eine akademische Karriere zu verzichten, und wie sie es geschafft hat, mit Unsicherheit umzugehen. Wir sprechen auch über praktischen Themen der Unternehmensgründung: Funding, Förderprogramme und die Frage, wie man ein Team nicht nur richtig stafft und führt, sondern auch bei Laune hält. Wer wissen will, wie Deep Tech mit ganz viel Expertise, Mut und einer Prise Zufall in echten Patientennutzen übersetzt wird, sollte unbedingt reinhören. Unsere neue Folge bietet eine spannende Mischung aus wissenschaftlicher Tiefe und authentischer -Gründerinnen-Erfahrung.

On the latest episode of the GZERO World podcast, Ian Bremmer talks with world-renowned cancer researcher and Pulitzer Prize-winning author Siddhartha Mukherjee about the future of medicine—and why artificial intelligence might finally tip the scales in the decades-long war on cancer.Cancer remains the second leading cause of death in the US, killing nearly 1,700 people every day. But Mukherjee says AI is already reshaping the field, from radiology and diagnostics to identifying new carcinogens and designing entirely new cancer drugs. “Every time we do this in collaboration with a machine,” he explains, “the machine learns it, and it learns it forever.”In a wide-ranging conversation, Mukherjee breaks down three major areas where AI is advancing medicine: patient care, data mining, and generative drug development. He also weighs in on early cancer detection, how inflammation may hold the key to understanding new carcinogens, and why this moment may be the most hopeful in half a century of cancer research.Host: Ian BremmerGuest: Siddhartha Mukherjee Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

On the latest episode of the GZERO World podcast, Ian Bremmer talks with world-renowned cancer researcher and Pulitzer Prize-winning author Siddhartha Mukherjee about the future of medicine—and why artificial intelligence might finally tip the scales in the decades-long war on cancer.Cancer remains the second leading cause of death in the US, killing nearly 1,700 people every day. But Mukherjee says AI is already reshaping the field, from radiology and diagnostics to identifying new carcinogens and designing entirely new cancer drugs. “Every time we do this in collaboration with a machine,” he explains, “the machine learns it, and it learns it forever.”In a wide-ranging conversation, Mukherjee breaks down three major areas where AI is advancing medicine: patient care, data mining, and generative drug development. He also weighs in on early cancer detection, how inflammation may hold the key to understanding new carcinogens, and why this moment may be the most hopeful in half a century of cancer research.Host: Ian BremmerGuest: Siddhartha Mukherjee Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

 In this week's episode, David and Ian discuss how precious metals and precious metals miners continue to do well, homebuilders are showing strength, lumber continuing to move lower, whether this is a start of a larger move in Biotech, areas of strength within small caps, moves in interest rates, and other areas of the market that are consolidating.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Robert F. Kennedy Jr. faced the Senate Finance Committee in a tense hearing amidst calls for the removal of the health secretary. The committee questioned Kennedy on his recent actions, including the firing of CDC director Susan Monarez. Meanwhile, the FDA's new rare disease pathway received mixed reactions, with some questioning its tangible impacts. AC Immune downsized and refocused its pipeline, while Kennedy proposed adding seven new vaccine advisors to the ACIP. Other news included successful RNA editing in an AATD study, demands for YouTube to remove anti-vaccine videos, and a new framework for rare disease approvals by the FDA. Thank you for tuning in to today's episode of Pharma and Biotech daily.

Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory firm for the life sciences sector, in a conversation focused on the current ‘perfect storm' in biotech and why the skies might not be quite as grey and foreboding as at first feared. Pashazadeh discusses how developers, CDMOs, CROs, and all other companies involved in therapeutic development might have to adjust to this new world. You can also listen to episode 203a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

AI is revolutionizing pharmaceuticals, moving from a side tool to a core driver of many aspects of the industry. Eli Lilly is leading the way, appointing Thomas Fuchs as its first Chief AI Officer to integrate AI across its pipeline. A NASA and Mount Sinai veteran, Fuchs is turning Lilly's data into a competitive edge. He joins Inside the ICE House to share how Lilly is building the AI-powered medicine company of the future.

Imagine unlocking a world where designing custom proteins is not only feasible - but faster, smarter, and more powerful than ever before, thanks to artificial intelligence.As the promise of programmable biology takes center stage, AI-driven protein engineering is rapidly moving from theoretical dream to industry standard.In this episode, David Brühlmann sits down with Elise de Reus, co-founder of Cradle, whose ground-breaking platform has become a go-to for luminaries at pharma giants, as well as leaders in agriculture and industrial biotech. Elise's journey bridges hands-on scientific discovery with entrepreneurial vision, and she's on a mission to make biology a foundational pillar of a more sustainable and equitable world.Here are three reasons you can't miss this episode:AI Unmasks the Black Box: Elise explains how Cradle's platform isn't just about predictive power - it offers transparency and actionable insights, allowing scientists to see why models perform as they do, and how to interpret and trust their outputs.From Hype to Real-World Impact: You'll hear real examples of AI accelerating everything from pandemic preparedness and antivenom development, to sustainable raw materials - plus candid advice on scaling AI adoption across diverse project teams.Blueprints for Biotech Founders: Elise shares hard-won lessons on transforming scientific innovation into a thriving company, including the counterintuitive power of targeting “mission impossible” challenges and the priceless value of early, unfiltered feedback.Ready to future-proof your protein engineering with generative AI? Press play to take home Elise's practical framework for evaluating tools, overcoming organizational hurdles, and crafting a winning adoption strategy, before the innovation curve pulls away.Wondering how Generative AI is transforming the biotech landscape? From accelerating regulatory workflows to reinventing protein purification, AI is driving breakthroughs across the industry. Explore these standout episodes to hear from experts leading the charge:Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresEpisodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian GuoEpisodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet SatwekarConnect with Elise de Reus:LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24Website: www.cradle.bioNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis has increased its commitment to its partnership with Argo BioPharma by an additional $5.2 billion, focusing on RNAi agreements targeting cardiovascular diseases. This highlights the ongoing advancements and challenges in the biopharmaceutical industry. Biotechs are turning to special purpose acquisition companies (SPACs) as a way to go public amid the IPO freeze. Gene therapy, with its potential to cure deadly diseases, is still facing challenges in terms of insurance coverage in the U.S. The industry is seeing a shift with some of the biggest biotech SPACs from the 2021 bubble no longer on the market. Meanwhile, Cytokinetics' cardiac myosin inhibitor, aficamten, has shown promising results in a phase III study for patients with obstructive hypertrophic cardiomyopathy. RFK Jr. has announced plans to reorganize chronic disease programs in the US to address high COVID-19 death rates. Companies like Novartis and Arrowhead are making significant commitments to various programs, while Trump's efforts to shore up the pharma supply chain with U.S. API are being questioned. Novartis continues its cutting spree with layoffs in New Jersey.These developments shed light on the evolving landscape of the biopharmaceutical industry.

In this episode of Data in Biotech, host Ross Katz talks with Jesper Ryge, Director of Computational Biology at Merck Germany. Jesper shares his journey from neuroscience labs to leading computational teams, offering deep insights into disease modeling, target discovery, and multi-omics integration. Discover how AI and spatial transcriptomics are shaping the future of pharma R&D. ​​What You'll Learn in This Episode >> How single-cell and spatial transcriptomics enhance disease mechanism discovery >> Why data integration and knowledge graphs are critical for target validation >> How computational biology teams interface with wet lab research >> What makes Merck Germany's data strategy unique in biotech >> How generative AI is changing how pharma interprets complex datasets Meet Our Guest Jesper Ryge is Director of Computational Biology at Merck Germany. A biophysicist by training, he brings deep expertise in neuroscience, single-cell analysis, and bioinformatics to pharmaceutical R&D. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about MerckConnect with Jesper Ryge on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

How can healthcare investment banking put patients—not just profits—at the center of biotech deals? In this episode, host James Zanewicz, JD, LLM, RTTP, speaks with Sam Libby, President and Managing Director of TCB Capital Advisors. Drawing from more than $20 billion in transactions across therapeutics, diagnostics, and digital health, Sam explains how TCB's unique advisory model partners with companies before and after deals close. From growing up with therapist parents to founding a merchant bank, Sam shares how personal values and professional experience can come together to shape smarter strategies for healthcare innovation. In this episode, you'll learn: Why patient-centered thinking belongs at the core of investment strategy. Common mistakes healthcare startups make when pitching to investors—and how to avoid them. The critical role of clinical data, mission alignment, and timing in building sustainable biotech companies. Tune in to learn how to navigate healthcare investments with purpose and ensure your biotech mission makes a lasting impact. Links: Connect with Sam Libby, and check out TCB Capital Advisors. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about Clairity and Informuta. Listen to our previous episode on Drug Pricing and Accessibility. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Russ Branzell, President and CEO of CHIME, sits down with Dr. Okan Ekinci, CMIO & Global Head of Digital Technology at Roche Information Solutions, to explore the evolving roles of digital health in one of the world's largest biotech organizations. From aligning diagnostics and pharmaceutical innovation to enhancing cybersecurity and unlocking AI's clinical potential, Dr. Ekinci shares how Roche is navigating digital transformation in healthcare on a global scale. This insightful conversation also addresses the cultural and leadership shifts necessary to sustain innovation and ensure long-term impact in healthcare and life sciences.Key Takeaways:Key challenges and opportunities in integrating diagnostic data with treatment decisions.Emerging frameworks to overcome data silos and drive clinical interoperability.Biotech-specific cybersecurity threats and strategies for balancing protection with innovation.The top technologies transforming patient care and shaping the future of precision medicine.Leadership imperatives for building a culture of sustainable innovation in life sciences.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The future of mental health is being transformed, moving beyond trial-and-error treatments to science-driven precision. Breakthroughs in neuroscience, AI, and precision medicine are mapping the brain's unique biological signatures, creating pathways for personalized care. Alto Neuroscience is at the forefront, using brain biomarkers and AI to match patients with the right therapies—fast. Founded in 2019 by Dr. Amit Etkin, the company is rewriting the rules of mental health treatment. He goes Inside the ICE house to explain how Alto is turning guesswork into guided science and offering hope where it once felt out of reach.

In this episode, we sit down with Eric Hauck, founder and CEO of Parasight Systems, to explore how a biotech hardware startup based in Lexington is solving one of veterinary medicine's most overlooked problems: parasite resistance caused by overmedication. From pasture animals to household pets, Parasight is building AI-powered diagnostic machines that make fecal testing easy, accurate, and accessible—replacing outdated lab work with push-button automation.Expect to learn how SBIR matching grants brought Hauck to Kentucky and helped launch a scalable biotech business, why animal diagnostics is a $100B opportunity growing 8% annually, how Parasight uses 3D printing and machine learning to rapidly iterate and improve its hardware, and why Lexington's mix of research, funding, and quality of life makes it a rising hub for hard tech innovation.Middle Tech is proudly supported by:KY Innovation → kyinnovation.comAwesome Inc → awesomeinc.orgDon't miss Awesome Inc's September 5 Across → ⁠⁠⁠Free Ticket for Middle Tech listeners

For decades, protein design has hinged on painstaking rounds of wet lab mutagenesis and trial-and-error, a process limited not by human ingenuity, but by time and complexity. Yet as the biotech field seeks faster, greener, and more effective solutions for therapeutics and industrial applications, the next leap might not come solely from the lab bench.In this episode, host David Brühlmann explores the frontiers of AI-driven protein engineering with Elise de Reus, co-founder of Cradle. Elise's journey weaves together a passion for DNA, real-world impact from the dairy industry to synthetic biology, and high-throughput experience at Zymergen. Now, at the helm of Cradle, she is bridging cutting-edge computational models with experimental validation, making biology programmable and accelerating the path from idea to functional protein.Here are three reasons this episode is essential listening:AI Makes Biology Programmable: Generative AI platforms like Cradle can intelligently design protein variants by learning from evolutionary trends and your own project data, enabling smarter, faster iterations and optimizing for stability, activity, and manufacturability - simultaneously.Limited Data? No Problem: While traditional approaches have stumbled over small, “short and fat” datasets, new generative AI models can effectively update their understanding with as little as a 96-well plate per round, democratizing high-impact protein design for startups, academia, and industry alike.The Future is Human + Machine: Even as algorithms advance, Elise stresses the irreplaceable value of wet lab validation. Cradle's hybrid approach, integrating experimental feedback with algorithmic prediction, ensures reliable, scalable results and empowers multidisciplinary teams to unlock first- and best-in-class solutions.Want to see how you can leverage AI to simplify and accelerate your own protein engineering projects? Don't miss this episode to hear how Elise and Cradle are transforming the pace - and possibilities - of biotech.Curious how Generative AI is reshaping biotech? From streamlining regulatory compliance to transforming protein purification, AI is changing the game. Dive into these standout episodes to explore the cutting edge of innovation in biotech:Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresEpisodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian GuoEpisodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet SatwekarConnect with Elise de Reus:LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24Website: www.cradle.bioNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA's ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O'Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.Show Notes Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening Paving the Way for Enhanced Drug Development A Status Report on Cell-Based Protein Arrays Retrogenix® Human Protein Library Retrogenix®: The Screen Door of Drug Development Retrogenix® CAR Specificity Testing Charles River Launched New Retrogenix Non-Human Protein Library 

In this episode, I talked to Dr. Samuel Stupp, Board of Trustees Professor of Materials Science, Chemistry, and Medicine at Northwestern University. He is one of the pioneers of supramolecular self-assembling materials and is a cofounder of multiple biotech startups, like Amphix Bio, that is working on regenerating spinal cords and tissues using biomaterials. ---------------------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoatNewsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.compromo code: DG Dubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c  Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##FDA approves new drug for rare genetic disorderThe FDA has recently approved a new drug for the treatment of a rare genetic disorder. This drug has shown promising results in clinical trials and is expected to provide much-needed relief for patients suffering from this condition. ##Major pharmaceutical company announces mergerA major pharmaceutical company has announced plans to merge with another company in the industry. This merger is expected to create a powerhouse in the pharmaceutical world, with the potential for significant growth and innovation. ##Biotech startup secures funding for groundbreaking researchA biotech startup has recently secured a substantial amount of funding to support their groundbreaking research in a new area of biotechnology. This funding will allow the company to further develop their technology and bring it to market in the near future. ##FDA issues warning about potential side effects of popular medicationThe FDA has issued a warning about potential side effects of a popular medication that is commonly used to treat a variety of conditions. Patients are advised to speak with their healthcare provider if they have any concerns about taking this medication. ##Pharma company announces breakthrough in cancer treatmentA pharmaceutical company has announced a major breakthrough in the treatment of cancer. Their new therapy has shown promising results in clinical trials and has the potential to significantly improve outcomes for cancer patients. ##Biotech firm partners with university on new drug developmentA biotech firm has partnered with a university on a new drug development project. This collaboration brings together the expertise of both organizations to advance research and bring new treatments to market. ##FDA approves expanded use of existing medicationThe FDA has approved the expanded use of an existing medication for the treatment of a different condition. This decision is based on new research showing the effectiveness of this medication in treating this additional condition.

FFINLO COSTAIN (8point9.com) and JOE STANLEY (GWCT Allerton Project), are joined by TOM PYCRAFT (Ark Summit), who's producing Land Alive at The Dairy Show this October 1st. This time:

We love to hear from our listeners. Send us a message. On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. is set to testify before the Senate Finance Committee on September 4. This comes after the removal of CDC Director Susan Monarez and the appointment of HHS Deputy Secretary Jim O'Neill as her interim replacement. Kennedy, along with FDA Commissioner Marty Makary and CBER Director Vinay Prasad, had previously been vocal against vaccine mandates during the COVID-19 pandemic, citing concerns about limiting medical choice. However, the FDA, under their leadership, has now approved updated COVID-19 vaccines with restrictions that go against this stance.RFK's vaccine restrictions are being viewed as restricting promised medical freedom. The FDA recently gave the green light to updated COVID-19 shots from Pfizer, Moderna, and Novavax but with certain limitations. This news comes as Teva introduces the first GLP-1 generic for obesity to the market, and J&J discontinues its rheumatoid arthritis program after disappointing mid-stage data. Kennedy's upcoming testimony highlights the ongoing turmoil within CDC leadership and raises questions about the conflicting messages surrounding vaccine mandates and medical freedom.

Edwin Gonzalez shares his journey from a BioBuilder apprentice to becoming a lead scientific support specialist at Thermo Fisher by age 23, highlighting how hands-on experiences and mentorship shaped his career path.• Middle school science teacher sparked Edwin's interest in science through engaging projects and supportive environment• First in his family to pursue science, without STEM role models at home• Joined BioBuilder apprenticeship program in 2019 after learning about it from a classmate• Gained first hands-on lab experience learning aseptic technique, pipetting, PCR, and bacterial transformation• Worked on biodesign project to create a device detecting airborne allergens• BioBuilder experience helped him decide to major in biology at Suffolk University• Skills learned at BioBuilder created foundation that made college coursework easier• Landed first industry position at Novo Nordisk through connections from a LabCentral internship• Currently works at Thermo Fisher as a lead scientific support specialist• Role combines lab operations, facilities management and direct research support• Recommends exploring multiple aspects of biology to build a diverse toolkit of experiencesLearn more about BioBuilder's programs for students, educators, and industry professionals here

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ohio is home to a multi-billion-dollar biotech industry. It's a growing sector that already employs more than 60,000 people and pays them above-average salaries. We'll be taking a deeper dive into biotech in Ohio.

We love to hear from our listeners. Send us a message. On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise. Swiss Rockets' portfolio of companies is developing radioligand therapies, vaccines, and cancer treatments, including bimiralisib for actinic keratosis. Cmiljanovic also discusses U.S. expansion plans, partnering, and funding strategies for early-stage companies.       Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/